|
|
|
|
|
|
Sponsors and Collaborators: |
Yale University National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00104975 |
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells that have been treated in the laboratory after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus before and after transplant may stop this from happening.
PURPOSE: This phase I trial is studying the side effects and best dose of donor lymphocytes when given after alemtuzumab and combination chemotherapy in treating patients who are undergoing donor stem cell transplant for hematologic cancer.
Condition | Intervention | Phase |
Chronic Myeloproliferative Disorders Leukemia Lymphoma Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases |
Drug: alemtuzumab Drug: fludarabine phosphate Drug: melphalan Drug: tacrolimus Drug: therapeutic allogeneic lymphocytes Drug: thiotepa Procedure: peripheral blood stem cell transplantation |
Phase I |
MedlinePlus related topics: | Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Lymphoma |
ChemIDplus related topics: | Melphalan Thiotepa Fludarabine Fludarabine monophosphate Tacrolimus Alemtuzumab Melphalan hydrochloride Sarcolysin Campath Tacrolimus anhydrous |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Reduced Intensity Conditioning Regimen for Haplo-Identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-Back of Non-Alloreactive T Cells |
Estimated Enrollment: | 20 |
Study Start Date: | February 2005 |
OBJECTIVES:
OUTLINE: This is a dose-escalation study of LMB-2 immunotoxin-treated, selectively-depleted donor T cells.
Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting-toxicity.
After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival.
PROJECTED ACCRUAL: A total of 15-20 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following hematologic malignancies:
Chronic myelogenous leukemia
Acute myeloid leukemia, meeting any of the following criteria:
Chronic lymphocytic leukemia
High-grade non-Hodgkin's lymphoma
Myeloproliferative disorders
Myelodysplastic syndromes (MDS), including any of the following:
Partially-matched related family donor available
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, Connecticut | |||||
Yale Cancer Center | |||||
New Haven, Connecticut, United States, 06520-8028 |
Yale University |
National Cancer Institute (NCI) |
Study Chair: | Erkut Bahceci, MD | Yale University |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000413698, YALE-25971, NCI-6765 |
First Received: | March 3, 2005 |
Last Updated: | May 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00104975 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|